Capital authorities announced that it will be until 2023 that the COVID-19 vaccine developed by the National Autonomous University of Mexico (UNAM) together with the Secretary of Education, Science, Technology and Innovation (SECTEI) of the CDMX.
Rosaura Ruiz Gutiérrez, Secretary of Education, Science, Technology and Innovation of the CDMXexplained that the capital government supported the university to have a BSL-3 containment laboratory that is required when working with a virus.
He explained that there are two vaccines that are being developed, however, the Biomedical Research Institute (IIBO) of the UNAM It is the one that is most advanced since it is going to start tests on people. “He’s got all the previous animal tests and now he’s going to have that second stage.”
Press conference 06/24/2022
–
–
–
–
He revealed that an agreement was signed to continue supporting the UNAM and to look for interested companies that want to support the mass production stage of the vaccine.
He explained that the specialists who work in the COVID-19 vaccine They explained that it is very up-to-date since variants of COVID-19 are continually appearing. He said that it is a “recombinant” vaccine, which is a protein and it is contemplated that it be permanently updated in the event of the appearance of variants.
He specified that the vaccine would be used as a booster and said he was confident that the large stage of experimentation in people would begin in January. “The UNAM he has to have his vaunca naturally”. He recalled that there is another vaccine, Patria, which is coordinated by Conacyt, with some institutions and that is more advanced.
The vaccine Patria is a project developed jointly by the Government of Mexico, through the National Council of Science and Technology, with Avimex Laboratories.
The vaccine project Patria has successfully passed the preclinical tests in living beings and the Phase 1 clinical study in humans, which were carried out between 2020 and 2021.
Currently, the Phase 2 clinical study of the booster of the vaccine is being carried out Patria with the aim of testing its effectiveness as a booster for those who already have a complete vaccination schedule.
The Phase 2 vaccine booster clinical study Patria requires the participation of more than 400 volunteers, so a call has been made to those interested to join this effort and register through this
link
.
adn40, always with me. Subscribe to our channel
Telegram
pfp
–
